FORMULATION DEVELOPMENT AND IN VITRO EVALUATION OF BUCCAL TABLETS OF TERBUTALINE SULFATE

The buccal terbutaline sulfate tablets were developed utilizing a direct compression method and several grades of HPMC polymers, such as K4M, K15M, and K100 M, with varied ratios and effects on drug release. The produced buccal tablets were tested in pre and post-compression studies. All formulation findings have been determined to be within pharmacopeia limitations. The most significant percentage of drug release for 10 hrs was 99.14% in the optimized formulation (F2) with HPMC K4M (15%), and the strength of the bioadhesive was determined to be 31.64 gm. F2 formulation, drug release kinetics followed zero-order release kinetics.

Keywords: Terbutaline sulfate, buccal tablets, HPMC, and bioadhesive strength